NEW CLINICAL EVIDENCES ABOUT COQ10 IN THE FIELD OF CARDIOVASCULAR HEALTHTHE EFFICACY OF COENZYME Q10 PHYTOSOME™ (UBIQSOME®) CONFIRMEDBY A NEW INDEPENDENT STUDY, FOCUSED ON ASTHENIA IN STATIN-USERS
Milan, February 27th 2024 - Dietary supplementation with CoQ10 PhytosomeTM (Indena’s UBIQSOME®)
effectively improves physical performance in older adults with statin-associated asthenia. This is the main
result of a recent independent study1 presented during the 32nd European Meeting On Hypertension And
Cardiovascular Protection (Milan, June 2023).
The double-blind, randomized, placebo-controlled study was aimed to investigate the effect of chronic dietary
supplementation with CoQ10 PhytosomeTM on physical performance maintenance in older adults with selfreported statin-associated asthenia.
The 60 subjects enrolled for the trial, 33 males and 27 women, were randomized to receive daily
supplementation either with placebo or 150 mg CoQ10 Phytosome™ for 8 weeks. At baseline, the subjects
were evaluated for clinical status, and by the execution of a physical examination and laboratory analyses.
After the first 4 weeks of supplementation, both groups significantly improved in asthenia compared tobaseline. Four more weeks later, the effect on asthenia was maintained, versus placebo and baseline, onlyin the supplemented group: statistical significance was reached both versus baseline and versus placebo.
This very encouraging data need to be confirmed with more thorough data.
“We’re very proud that UBIQSOME®, our coenzyme Q10 formulated with PhytosomeTM, the proprietary
Technology Platform developed by Indena, has been useful for the trial – says Serena Tongiani, Chief
Product Officer at Indena –. And of course we’re very happy that this preliminary clinical evidences confirm
the values of our product in the field of cardiovascular health. We’ve been working to confirm ourUBIQSOME® as the leader in muscle uptake CoQ10 supplementation. This independent study is consistent
with the capacity of UBIQSOME® to reach the right biological target, and indicates its potential in case ofasthenia in statin-users. Another important result for our portfolio”.
As known, coenzyme Q10 plays a central role in generation and regulation of cell bioenergy, being involvedin transferring of electrons within the mitochondrial oxidative respiratory chain and hence, ATP production,and has reported to have antioxidant and beneficial effects in improving human health and well-being. On
the other hand, CoQ10 has a low oral bioavailability, due to its poor water solubility, high molecular weight,
low solubility in lipids and low intestinal permeability.
UBIQSOME® is the innovative food grade delivery system of coenzyme Q10 formulated with the proprietary
Multi-Talented Technology Platform developed by Indena. It’s Phytosome™, the breakthrough 100% foodgrade delivery system that optimizes the performance of many natural actives in multiple ways, allowing toexploit their power and health benefits. Today, Phytosome™ is the most reliable and customizable solution
in the nutraceutical field.
Thanks to its Phytosome™ formulation, UBIQSOME® is a food-grade highly absorbable form, standardized
in coenzyme Q10 (18-22% by HPLC), which optimizes coenzyme Q10 levels not only in blood but also inmuscles. Indeed, the scientifically demonstrated significative presence of CoQ10 at muscular level
represents a unique and successful goal which unequivocally differentiates UBIQSOME® from otheringredients.
Indena is committed to driving progress towards the UN’s Sustainable Development Goals, aiming at putting
sustainability first – from raw materials sourcing to production and marketing – with a focus on environmental
impact, use of renewable energies and building a more circular economy.
1Cicero, Arrigo, et al. Effect of coenzyme q10 on muscular strength in elderly patients with statin-associated asthenia: a double-blind,randomized, placebo-controlled clinical trial." Journal of hypertension 41.1 (2023): e152-e153.

Indena SpA is an Italian company, a global leader in the identification, development, production and sale of extracts and pure activeingredients, mainly derived from medicinal plants, for use in the pharmaceutical, health food, cosmetics and veterinary industries.
Backed up by a century of botanical experience, the company owns 100 patent families, has published more than 1000 scientific studies
and co- operates with the world’s most prestigious universities and private research institutions. Indena employs over 900 staff, investinga significant amount of its annual turnover in research, making this activity the key to its success. Headquartered in Milan, Indena has
4 production sites and 5 international branches throughout the world and manages sales in more than 80 countries. The company's
experts communicate and interact constantly with the major international regulatory authorities and cooperate on the update of all themain pharmacopoeias.
Find more on indena.com

Indena press contacts
bcw-burson cohn & wolfe
Luisa Cavagnera: luisa.cavagnera@bcw-global.com
Ph. +39 3497665890